| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H22N4O2S2 |
| Molecular Weight | 294.437 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCC(=O)NCCSSCCNC(=O)CCN
InChI
InChIKey=WELIVEBWRWAGOM-UHFFFAOYSA-N
InChI=1S/C10H22N4O2S2/c11-3-1-9(15)13-5-7-17-18-8-6-14-10(16)2-4-12/h1-8,11-12H2,(H,13,15)(H,14,16)
Alethine (Beta alethine) is an immunostimulant agent. It was undergoing clinical development with LifeTime Pharmaceuticals for the treatment of haematological malignancies. It is a low molecular weight disulfide that has been shown to exhibit in vivo antitumor activity in murine myeloma and melanoma models.
Originator
Approval Year
PubMed
Sample Use Guides
3 different doses of Alethine that were logs apart (30 mg/kg, 30 ug/kg, and 600 ng/kg) either alone or in combination with low dose (10 ug per mouse for a total of 3 doses 3 days apart) anti-PD1 in the DBA mouse Cloudman melanoma mouse model were tested. The lowest dose of Alethine (600 ng/kg) in combination with anti-PD1 resulted in cures in 33% of the mice when treatment was initiated when tumors were of substantial size (average size of 30 mm2).
Route of Administration:
Other
Alethine stimulated the HPBLS and murine splenocytes to produce immunoglobulinin a dose-dependent manner, with illustrated optimal concentrations of about 5-10 ng/ml culture. In HPBLS, comparatively little antibody production and nominal thymidine incorporation were observed with alethine at concentrations below 1 ng/ml (5-500 pg/ml).
SUBSTANCE RECORD
